menu
    • menu
    [{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Cantor Fitzgerald & Co"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"ROCK 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kadmon Holdings \/ Not Applicable"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kadmon Holdings \/ Not Applicable"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kadmon Holdings","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Kadmon Holdings \/ Sanofi"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Meiji Seika Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Kadmon Holdings \/ Meiji Seika Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Belumosudil Mesylate

    Menu

    Belumosudil Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rezurock® (Belumosudil) Patient-reported Outcomes Correlated With Clinical Response in Chronic Graft-versus H...

                            Details : Results demonstrate strong, but not universal, correlation between organ clinical responses and clinically meaningful improvements in patient-reported outcomes from a pooled analysis of ROCKstar and KD025-208 for Rezurock (belumosudil) clinical trials.

                            Brand Name : Rezurock

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 21, 2022

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi to Acquire Kadmon to Further Strengthen Growth of Transplant Business

                            Details : The acquisition supports Rezurock™(belumosudil) to its transplant portfolio. Rezurock is a FDA-approved, treatment for chronic graft-versus-host disease for adult and pediatric patients 12 years and older who have failed at least two prior lines of sys...

                            Brand Name : Rezurock

                            Molecule Type : Small molecule

                            Upfront Cash : $1,900.0 million

                            September 08, 2021

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

                            Details : The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2).

                            Brand Name : KD025-209

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2021

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease

                            Details : In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of belumosudil has been extended to August, 2021.

                            Brand Name : KD025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 11, 2021

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Cantor Fitzgerald & Co

                            Deal Size : $240.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Mill...

                            Details : Kadmon plans to use a part of the proceeds to prepare to commercialize belumosudil for chronic graft-vs-host disease in the U.S; for its clinical-stage product candidates; for discovery and preclinical studies of other product candidates; and for general...

                            Brand Name : KD025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Cantor Fitzgerald & Co

                            Deal Size : $240.0 million

                            Deal Type : Public Offering

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting

                            Details : The presentation will include 12-month efficacy and safety data and key secondary endpoints including duration of response, Failure-Free Survival, steroid dose reductions and quality-of-life improvements.

                            Brand Name : KD025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 04, 2020

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic G...

                            Details : The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD who failed two or more lines of systemic therapy.

                            Brand Name : KD025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis

                            Details : Belumosudil is being studied in an ongoing double-blind, placebo-controlled Phase 2 clinical trial in adults with SSc. The study is enrolling 60 patients to receive belumosudil 200 mg QD, belumosudil 200 mg BID or placebo for 24 weeks.

                            Brand Name : KD025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2020

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility

                            Details : The proceeds from the offering will be used to advance belumosudil toward a NDA filing with the U.S FDA and support related pre-commercialization activities and provide additional working capital for general corporate purposes.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 05, 2020

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host...

                            Details : Belumosudil achieved clinically meaningful and statistically significant Overall Response Rates of 73% with 200 mg once daily and 74% with 200 mg twice daily. Responses were achieved across key patient subgroups and complete responses were observed in al...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2020

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth